CPC A61K 31/5415 (2013.01) [A61K 31/135 (2013.01); A61K 31/138 (2013.01); A61K 31/155 (2013.01); A61K 31/4418 (2013.01); A61K 31/444 (2013.01); A61K 31/4453 (2013.01); A61K 31/505 (2013.01); A61K 31/5355 (2013.01); A61K 31/7135 (2013.01); A61K 45/06 (2013.01); A61P 43/00 (2018.01)] | 7 Claims |
1. A method for treating a subject having or suspected of having alpha-1-antitrypsin deficiency (ATD), wherein the subject has not developed hepatocellular carcinoma, the method comprising: administering to the subject a therapeutically effective amount of a composition comprising one or more of a proteotoxicity reducing agent selected from Tricyclic antipsychotics, Vasodilators, Antibiotics/Antiseptics, and Aryl piperazines.
|